Dosing, the limitations of susceptibility testing, and use of alternate therapies are all discussed in the IDSA's guidelines for treating MRSA infections.
The Infectious Diseases Society of America (IDSA) has published its first set of guidelines for the treatment of MRSA infections in both adults and children.
Published in Clinical Infectious Diseases, the guidelines address issues related to the use of vancomycin therapy in the treatment of MRSA infections, including dosing and monitoring, current limitations of susceptibility testing, and the use of alternate therapies for those patients with vancomycin treatment failure and infection due to strains with reduced susceptibility to vancomycin.
One of the primary topics addressed by the guidelines is the management of skin and soft-tissue infections (SSTIs) in the era of community-associated MRSA.
In terms of SSTIs, Catherine Liu, MD, of the University of California, San Francisco, and colleagues recommend the following:
In pediatric patients, the recommendations are as follows:
To access the full guidelines, click here.